Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taebeom Kim

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
BMC Proceedings|December 17, 2016
Incorporating ENCODE information into association analysis of whole genome sequencing dataTaebeom Kim, Peng Wei
Scientific Reports|May 27, 2022
Impact of sweet, umami, and bitter taste receptor (TAS1R and TAS2R) genomic and expression alterations in solid tumors on survivalRyan M Carey, TaeBeom Kim, Noam A Cohen, et al.
BMC Proceedings|December 19, 2014
Small sample properties of rare variant analysis methodsMichael D Swartz, Taebeom Kim, Jiangong Niu, et al.
Molecular Cancer Research : MCR|August 9, 2017
Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal CanalVan Morris, Xiayu Rao, Curtis Pickering, et al.
American Journal of Hematology|January 11, 2022
Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta-analysisMalgorzata K Nowakowska, Taebeom Kim, Mikayla T Thompson, et al.
Molecular Oncology|October 30, 2021
T2R bitter taste receptors regulate apoptosis and may be associated with survival in head and neck squamous cell carcinomaRyan M Carey, Derek B McMahon, Zoey A Miller, et al.
Cell Reports|November 23, 2023
Lidocaine induces apoptosis in head and neck squamous cell carcinoma through activation of bitter taste receptor T2R14Zoey A Miller, Arielle Mueller, TaeBeom Kim, et al.
JCO Precision Oncology|February 2, 2022
Clinical and Molecular Characterization of <i>POLE</i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced CancersBenjamin Garmezy, Jinesh Gheeya, Heather Y Lin, et al.
Blood Advances|June 3, 2024
Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomesKevin T Nead, Taebeom Kim, LiJin Joo, et al.
European Urology Oncology|November 5, 2025
Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade SamplesRoberto Ruiz-Cordero, Qi Wang, Gayatri Kumar, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
BMC Proceedings|December 17, 2016
Incorporating ENCODE information into association analysis of whole genome sequencing dataTaebeom Kim, Peng Wei
Scientific Reports|May 27, 2022
Impact of sweet, umami, and bitter taste receptor (TAS1R and TAS2R) genomic and expression alterations in solid tumors on survivalRyan M Carey, TaeBeom Kim, Noam A Cohen, et al.
BMC Proceedings|December 19, 2014
Small sample properties of rare variant analysis methodsMichael D Swartz, Taebeom Kim, Jiangong Niu, et al.
Molecular Cancer Research : MCR|August 9, 2017
Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal CanalVan Morris, Xiayu Rao, Curtis Pickering, et al.
American Journal of Hematology|January 11, 2022
Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta-analysisMalgorzata K Nowakowska, Taebeom Kim, Mikayla T Thompson, et al.
Molecular Oncology|October 30, 2021
T2R bitter taste receptors regulate apoptosis and may be associated with survival in head and neck squamous cell carcinomaRyan M Carey, Derek B McMahon, Zoey A Miller, et al.
Cell Reports|November 23, 2023
Lidocaine induces apoptosis in head and neck squamous cell carcinoma through activation of bitter taste receptor T2R14Zoey A Miller, Arielle Mueller, TaeBeom Kim, et al.
JCO Precision Oncology|February 2, 2022
Clinical and Molecular Characterization of <i>POLE</i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced CancersBenjamin Garmezy, Jinesh Gheeya, Heather Y Lin, et al.
Blood Advances|June 3, 2024
Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomesKevin T Nead, Taebeom Kim, LiJin Joo, et al.
European Urology Oncology|November 5, 2025
Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade SamplesRoberto Ruiz-Cordero, Qi Wang, Gayatri Kumar, et al.
Pageof 2